Complicated Skin And Skin Structure Infections (cSSSI) Pipeline Review, H2 2015 Is Released Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline Review, H2 2015 Summary Global Markets Direct s, Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline Review, H2 2015, provides an overview of the Complicated Skin And Skin Structure Infections (cSSSI) s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Complicated Skin And Skin Structure Infections (cSSSI), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Complicated Skin And Skin Structure Infections (cSSSI) and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Complicated Skin And Skin Structure Infections (cSSSI) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Complicated Skin And Skin Structure Infections (cSSSI) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Complicated Skin And Skin Structure Infections (cSSSI) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects Coverage of the Complicated Skin And Skin Structure Infections (cSSSI) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Complicated Skin And Skin Structure Infections (cSSSI) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Complicated Skin 1
And Skin Structure Infections (cSSSI) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Browse with TOC @ http://www.idatainsights.com/reports-landing-page.php?id=173384/complicatedskin-and-skin-structure-infections-csssi-pipeline-review-h2-2015 To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landingpage.php?id=173384/complicated-skin-and-skin-structure-infections-csssi-pipeline-review-h2-2015 Table of Contents
Introduction 5 Global Markets Direct Report Coverage 5 Complicated Skin And Skin Structure Infections (cSSSI) Overview 6 Therapeutics Development 7 Pipeline Products for Complicated Skin And Skin Structure Infections (cSSSI) - Overview 7 Complicated Skin And Skin Structure Infections (cSSSI) - Therapeutics under Development by Companies 8 Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Early Stage Products 11 Complicated Skin And Skin Structure Infections (cSSSI) - Products under Development by Companies 12 Complicated Skin And Skin Structure Infections (cSSSI) - Companies Involved in Therapeutics Development 13 CrystalGenomics, Inc. 13 Debiopharm International S.A. 14 Dong-A Socio Group 15 GlaxoSmithKline Plc 16 Melinta Therapeutics, Inc 17
2
MicuRx Pharmaceuticals, Inc. 18 Motif Bio Plc 19 Phosphagenics Limited 20 Complicated Skin and Skin Structure Infections (cSSSI) - Therapeutics Assessment 21 Assessment by Monotherapy Products 21 Assessment by Target 22 Assessment by Mechanism of Action 24 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Drug Profiles 29 CG-400549 - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Debio-1450 - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Debio-1452 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 delafloxacin - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 gepotidacin mesylate - Drug Profile 37 3
Product Description 37 Mechanism of Action 37 R&D Progress 37 iclaprim mesylate - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 MRX-I - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Small Molecule for Complicated Skin and Skin Structure Infections - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Small Molecules to Inhibit DHFR for Infectious Diseases - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 tedizolid phosphate - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Complicated Skin And Skin Structure Infections (cSSSI) - Recent Pipeline Updates 48 Complicated Skin And Skin Structure Infections (cSSSI) - Dormant Projects 65 Complicated Skin and Skin Structure Infections (cSSSI) - Product Development Milestones 66
4
Featured News & Press Releases 66 Sep 29, 2015: Motif Announces Presentation of Two Posters on Iclaprim at ID Week 2015 66 Sep 03, 2015: FDA Grants Fast Track Designation for Iclaprim 66 Aug 24, 2015: Potent Efficacy of Iclaprim Confirmed in Independent Laboratory Study 67 Apr 30, 2014: Cubist to Present New Pipeline Data Of Tedizolid Phosphate At 2014 European Congress of Clinical Microbiology and Infectious Diseases 67 Oct 22, 2013: Cubist Announces Submission of New Drug Application for Investigational Antibiotic Tedizolid for Treatment of Serious Skin Infections 68 Sep 04, 2013: Affinium Pharmaceuticals Announces the Initiation of a Phase 1 Intravenous Clinical Trial of a New Antibiotic Prodrug 69 Appendix 71 Methodology 71 Coverage 71 Secondary Research 71 Primary Research 71 Expert Panel Validation 71 Contact Us 71 Disclaimer 72
Read More http://www.idatainsights.com/reports-landing-page.php?id=173384/complicated-skinand-skin-structure-infections-csssi-pipeline-review-h2-2015 About Us: iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line. ContactUs: iData Insights Tel: 1-866-237-2965
5
Web: http://www.idatainsights.com Email: info@idatainsights.com About iData Insights We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects
6
7